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Introduction
Almost every type of animal cell has the capacity to synthesize 
heparan sulfate (HS). The HS polysaccharide is composed of 
alternating hexuronic acid and d-glucosamine units and is sub-
stituted with sulfate groups in various positions. The sulfated 
saccharide domains provide numerous docking sites for protein 
ligands and are abundantly expressed at cell surfaces and in the 
extracellular matrix as part of proteoglycans (PGs). Two main 
types of cell surface–bound PG core proteins have been iden-
tifi  ed: the glycosylphosphatidyl inositol–linked glypicans and 
the transmembrane syndecans; both types are thought to be ex-
pressed in high copy numbers (up to 10
6 per cell; Bernfi  eld et al., 
1992). The diverse ligands include growth factors/morphogens 
and their receptors, enzymes, enzyme inhibitors, cell adhesion 
molecules, chemokines, various extracellular matrix proteins, 
and microbial proteins (Bernfi  eld et al., 1999). Interactions with 
HS contribute to or modify the various protein functions, which 
are of particular interest in relation to growth factor/morphogen 
translocation and signaling (Fig. 1). Thus, HSPGs are essential 
for normal embryonic development but are also implicated in 
homeostasis as well as in pathological processes of growing and 
adult individuals (Hacker et al., 2005).
The HS backbone typically contains 50–400  monosaccharide 
units. The hexuronic acid moieties are of two kinds: d-glucuronic 
acid (GlcA) and l-iduronic acid (IdoA). The extreme structural 
diversity typical of HS species is a result of the variable distri-
bution of these residues as well as of sulfate substituents along 
the chain. Because this diversity appears to be strictly regulated, 
it is currently believed to enable selective interaction with pro-
teins in a topologically and temporally controlled manner (Esko 
and Lindahl, 2001). The aim of this present review is to reassess 
this concept in view of recent fi  ndings.
Regulated polymer modiﬁ  cation 
in HS biosynthesis
Nascent HS chains evolve by the stepwise addition of alternat-
ing GlcA and N-acetylglucosamine (GlcNAc) residues to ac-
ceptor linkage region oligosaccharides, which are substituted 
on PG core proteins. These chains are subsequently modifi  ed 
through several consecutive steps, including N- deacetylation 
and N-  sulfation of GlcNAc residues, C5 epimerization of GlcA 
to IdoA, and O-sulfation in various positions (Esko and Lindahl, 
2001). The process, which is outlined in Fig. 2, is generally in-
complete, such that the fi  nal products display a domain-type 
arrangement of more or less modifi  ed saccharide sequences. 
Because of the substrate specifi  cities of the enzymes involved 
(at least in part), IdoA and O-sulfate residues are accumulated in 
domains of contiguous N-sulfated (NS) disaccharide units (NS 
domains), are less abundant in regions of mixed N- substitution, 
and are essentially lacking in contiguous N-acetylated sequences. 
Heparin, which is produced by connective tissue–type mast 
cells, is the result of extensive biosynthetic polymer modifi  -
cation and may be conceived as an extended, highly N- and 
O-sulfated IdoA-rich NS domain.
Analysis of HS from different mammalian tissues revealed 
the tissue-specifi  c composition of samples, pointing to strict 
regulation of biosynthetic polymer modifi  cation (Maccarana 
et al., 1996; Ledin et al., 2004). Anion exchange chromato-
grams of products obtained by chemical or enzymatic degra-
dation of mouse HS thus differed for samples from different 
tissues but were virtually superimposable for corresponding 
samples from different individuals. Moreover, immunohisto-
chemical analysis showed selective, reproducible distribution 
of distinct HS epitopes within a given tissue (van Kuppevelt 
et al., 1998). These fi  ndings could refl  ect differences in saccha-
ride domain composition, sequence, and/or overall organiza-
tion, which are potentially required to selectively bind different 
protein ligands.
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Proteins share binding sites in HS
What do we know regarding specifi  city in HS–protein interac-
tions? Early evidence for specifi  city was the antithrombin-binding 
sequence, which is responsible for the clinically exploited 
blood anticoagulant activity of heparin (Lindahl et al., 1980). 
Each one of the sulfate substituents of this GlcNAc6S-GlcA-
GlcNS3S-IdoA-GlcNS pentasaccharide structure is essential 
for high affi  nity interaction with antithrombin and, thus, for 
  anticoagulant activity. Notably, this sequence contains the rare 
glucosamine 3-O-sulfate group in addition to the more common 
2-O-sulfate of IdoA and N- and 6-O-sulfate groups of GlcN 
  residues. Another unusual structure based on a 3-O-sulfated 
N-unsubstituted GlcN3S unit mediates the apparently specifi  c 
binding of herpes simplex gD protein to the cell surface HS dur-
ing viral infection (Shukla et al., 1999). What about the multi-
tude of other heparin-binding proteins that depend on the 
interaction with endogenous HS ligands for biological activity? 
We previously proposed that the common sulfate substituents 
could also be arranged in a sequence-specifi  c manner to provide 
selective protein binding (Salmivirta et al., 1996). Such epitopes 
would be masked in the highly sulfated heparin molecule, thus 
explaining the apparently nonselective protein binding to this 
polysaccharide. However, although recent binding studies with 
selected proteins have shown that a particular kind of sulfate 
group (e.g., 6-O-sulfates) might contribute more to interaction 
than others (Ashikari-Hada et al., 2004), there is yet no clear 
evidence of distinct sequence specifi  city based on the distribu-
tion of common sulfate residues (Powell et al., 2004). Various 
signaling proteins may be considered in this context.
Different members of the FGF family share binding sites 
on the HS chain, and their affi  nities for HS-related oligosaccha-
rides generally correlate with the overall degree of saccharide 
sulfation (Jemth et al., 2002; Kreuger et al., 2005; however, see 
Ashikari-Hada et al., 2004 regarding preferential binding of 
variously O-sulfated oligosaccharides). Our recent experiments 
suggest that a relatively nonspecifi  c charge interaction may also 
prevail in the formation of FGF–HS–FGF receptor complexes 
(Fig. 2). Using a variety of oligo- and polysaccharide probes, we 
found that the complex formation of FGF1 or FGF2 with their 
various receptors was increasingly promoted by saccharide se-
quences of increasing overall sulfate content in an apparently 
nonspecifi  c fashion. Heparin oligosaccharides were generally 
the most effi  cient complex promoters, whereas less sulfated HS 
species were less effi  cient (Jastrebova et al., 2006). These fi  nd-
ings suggest that the dependence of FGF signaling on HS fi  ne 
structure may be less critical than previously anticipated. How-
ever, we note studies claiming that NS oligosaccharide frac-
tions derived from authentic HS contained receptor-activating 
as well as nonactivating species (Pye et al., 1998; Guimond and 
Turnbull, 1999). Of course, many ligand–receptor combinations 
remain to be examined, and we cannot exclude elements of se-
lectivity here that are currently unrecognized.
The role of VEGF as a key regulator of vascular develop-
ment is well documented (Carmeliet et al., 1996). The interac-
tion of the long splice variant VEGF-A165 with HS is essential for 
proper signaling, as recently demonstrated in variously designed 
cell culture systems (Ashikari-Hada et al., 2005;   Jakobsson 
et al., 2006). Studies aimed at defi  ning the structural features of 
HS that are required for VEGF-A165 binding implicated all com-
mon sulfate groups (N, 2-O, and 6-O), although with different 
emphasis on their relative importance (Ashikari-Hada et al., 
2005; Robinson et al., 2006). Moreover, the pleiotropic hepato-
cyte growth factor binds a variety of glycosaminoglycan struc-
tures without any clear preference (Catlow et al., 2003).
Knockout clues from embryology
Mice that were genetically defi  cient in enzymes involved in HS 
biosynthesis provided novel insight into the question of speci-
fi  city in HS–protein interactions. Phenotype analysis revealed 
developmental events that require the involvement of HS, and 
structural analysis of the corresponding polysaccharides could, 
in some cases, pinpoint molecular features that are of critical 
importance to such events. Equally important, however, is to 
identify HS-dependent events that remain unperturbed in spite 
of deranged HS structure.
Embryos lacking GlcA/GlcNAc transferase 1 (EXT1), 
which generates the initial (GlcA-GlcNAc)n  polysaccharide 
chain (Fig. 2), failed to undergo proper gastrulation in accord 
with the recognized need for HS in early patterning events (Lin 
et al., 2000). In contrast, the targeted disruption of genes encod-
ing selected enzymes involved in the later stages of HS bio-
synthesis resulted in strikingly varied phenotypes. These mice 
displayed variously perturbed HS structures and a variety of de-
velopmental abnormalities but also displayed features assumed 
Figure 1.  Proposed roles of HSPGs in growth 
factor/morphogen signaling. Locally produced 
and secreted protein ligands (e.g., growth fac-
tors) (1) are captured by HS chains and accu-
mulate at the cell surface (2). Interactions with HS 
support the generation of protein gradients (3). 
HS chains promote stable interactions between 
growth factors and receptors and, thus, modu-
late the quality of receptor signaling (such as 
amplitude and kinetics of activation/inactiva-
tion; 4). HSPGs may also regulate the turnover 
of receptors and participate in the internal-
ization of receptor complexes (5). Shedding 
of HSPG ectodomains (Kreuger et al., 2004) 
or degradation of HS chains by heparanase 
(Vlodavsky and Friedmann, 2001) may release 
HS-bound ligands from the cell surface (6).HEPARAN SULFATE–PROTEIN INTERACTIONS • KREUGER ET AL. 325
to be HS dependent that were surprisingly normal. For example, 
brain-selective, conditional EXT1 knockout, which was aimed 
at identifying HS-dependent processes in cerebral development, 
resulted in multiple brain defects, as predicted from the estab-
lished involvement of various HS-dependent growth factors 
(in particular FGF8; Inatani et al., 2003). Yet, mice lacking the 
C5 epimerase catalyzing the conversion of GlcA to IdoA resi-
dues (Li et al., 2003) or the 2-O-sulfotransferase required for 
IdoA 2-O sulfation (Bullock et al., 1998; Merry et al., 2001) 
showed no obvious brain phenotype irrespective of the severely 
deranged HS structures. Moreover, assessment of the cardio-
vascular system pointed to VEGF signaling that is compatible 
with adequate vasculogenesis and angiogenesis. The elevated 
N- and 6-O-sulfation, which is characteristic of these mutated 
HS species, apparently suffi  ced to satisfy the requirement for 
HS in important VEGF and FGF signaling events (Fig. 2). Also, 
other organ systems, such as the gastrointestinal tract, which is 
known to require HS for growth factor/morphogen signaling in 
development, appeared normal in the C5 epimerase and 2-O-
  sulfotransferase knockout mice.
Certain other events failed, however, as indicated by the 
kidney agenesis, the skeletal malformations, and other problems 
leading to early postnatal death of the animals. Interestingly, 
the kidney agenesis was not observed in N-deacetylase/ 
N-sulfotransferase-1–null mice, which were defi   cient in the 
early N-deacetylation/N-sulfation step (Ringvall et al., 2000); 
the overall poorly modifi  ed but IdoA-containing HS that  resulted 
apparently functioned at a critical stage of kidney   induction. 
Moreover, the lung phenotype caused by C5 epimerase defi  -
ciency (HS lacking IdoA and IdoA2S residues) was not seen in 
mice lacking 2-O-sulfotransferase (HS containing IdoA but no 
IdoA2S units; Fig. 2). Redundant O-sulfation was also observed 
in Drosophila melanogaster 2-O- or 6-O-  sulfotransferase–null 
mutants that were able to complete development with apparently 
normal FGF signaling and morphology (Kamimura, K., and 
H. Nakato, personal communication). Lack of both enzymes, 
on the other hand, led to impaired FGF signaling and multiple 
patterning defi  ciencies. We conclude that several functionally 
important HS–protein interactions depend primarily on charge 
distribution, whereas others may require the presence of spe-
cifi  c saccharide components. In this perspective, what is the 
functional purpose of the strict regulation of polymer modifi  ca-
tion in HS biosynthesis?
Regulated domain organization?
The rationale for stringent HS biosynthesis may relate primar-
ily to the domain organization of HS chains. Variously designed 
interaction studies implicate saccharide sequences of up to 
12-mer size (in some cases even longer) for effi  cient interac-
tion with proteins (Schlessinger et al., 2000; Gallagher, 2001). 
  Contiguous NS domains of >8-mer size are generally rare in HS. 
Instead, composite binding sites involving short NS domains 
separated by N-acetylated disaccharide units (N-sulfated/ 
acetylated/sulfated [SAS] domains) can mediate interactions 
with monomeric (e.g., endostatin; Kreuger et al., 2002) as well 
as oligomeric (e.g., interferon-γ [Lortat-Jacob et al., 1995], 
  interleukin-8 [Spillmann et al., 1998], and platelet factor 4 
[Stringer and Gallagher, 1997]) protein ligands. Also, VEGF-A165 
occurs as a dimer that interacts with SAS domains in HS chains 
(Fig. 2; Robinson et al., 2006). Given the size of saccharide domains 
that are implicated in complex formation with growth factors 
and their receptors, we predict that SAS-type structures may 
be involved or even required in various signaling complexes. 
In fact, the differential complex formation of endogenous HS 
in mouse embryos with defi  ned/given FGF–FGF receptor pairs 
(Allen and Rapraeger, 2003) may well refl  ect selective domain 
spacing rather than precisely tailored saccharide sequences.
Figure 2.  Biosynthesis of HS and molecular phenotypes resulting from 
deﬁ   cient HS biosynthetic enzymes. See Esko and Lindahl (2001) and 
Hacker et al. (2005). HS chains are synthesized while attached to core 
protein serine residues through a GlcA-Gal-Gal-Xyl linkage region. The lin-
ear HS chain is thereafter polymerized through the action of GlcNAc- and 
GlcA-transferases belonging to the EXT family and further modiﬁ  ed  by 
  partial N-deacetylation/N-sulfation (N-deacetylase/N-sulfotransferase) to 
yield NS disaccharide units. Consecutive stretches of such units (NS do-
mains) are hotspots for further modiﬁ   cations: a C5 epimerase converts 
GlcA to IdoA followed by variable O-sulfation at C-3 and C-6 (red circles) 
of GlcN and at C-2 (yellow circles) of IdoA (and some GlcA) units. 
  Completed chains may be further edited by endo-6-O-sulfatases (Ai et al., 
2003). Protein ligands interact with single NS domains (e.g., FGFs) or with 
NS domains separated by N-acetylated disaccharide residues (SAS do-
mains; illustrated here for VEGF-A165 [Robinson et al., 2006]; and FGF–
HS–FGF receptor complexes). The bottom model depicts a molecular 
phenotype of C5 epimerase
−/− HS that lacks IdoA and IdoA 2-O-sulfation 
but is more extensively N- and 6-O-sulfated than the corresponding wild-type 
product. The 2-O-sulfotransferase
−/− HS is similar to the C5 epimerase
−/− 
polysaccharide except for the presence of IdoA (Merry et al., 2001). 
HS from C5 epimerase
−/− or 2-O-sulfotransferase
−/− cells may still interact 
more or less efﬁ  ciently with many protein ligands (see Knockout clues from 
embryology). Blue boxes, NS domains containing GlcA and/or IdoA; 
  yellow boxes, NS domains containing GlcA but no IdoA.JCB • VOLUME 174 • NUMBER 3 • 2006  326
We propose that polymer modifi  cation in HS biosynthesis 
is primarily regulated with regard to domain distribution and de-
gree of sulfation (i.e., the distribution of N-substituents and the 
levels of 2-O- and 6-O-sulfation). Such regulation would pre-
sumably suffi  ce to explain the observed consistent differences 
in composition between HS species from different cellular or 
tissue sources (Maccarana et al., 1996; Ledin et al., 2004). The 
resultant clusters of negative charge will determine interactions 
with proteins that may be relatively nonselective with sharing/
overlap of saccharide target sequences between different pro-
tein ligands. Given the excessive number of possible saccharide 
epitopes, specifi  c sequences based on common constituents that 
provide somewhat stronger binding of a particular protein li-
gand than other sequences may well be preferentially formed in 
the course of such regulated polymer modifi  cation. More selec-
tive interactions would require either sequences containing rare 
components or precise spacing of two (or more) sulfated do-
mains (SAS arrangement). Notably, there is no method readily 
available to reveal the detailed distribution of various domains 
along a native HS chain, although some progress has been 
reported based on selective lyase degradation of the polymer 
(Murphy et al., 2004). In addition, we still do not understand 
the regulatory mechanisms in HS biosynthesis that determine 
domain generation or localization.
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